adialpharma.com (ADIL): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Adial Pharmaceuticals (ADIL) maintains an environmental policy limited to basic waste disposal and energy saving within its laboratories. The stock price history allows for the tracking of EV/EBITDA, which currently stands at 0.00. The company's business moat relies on unique patents for combating alcoholism and lobbyist support under strict FDA oversight. Adial Pharmaceuticals (ADIL) currently generates no consistent profit, as its medications are still undergoing clinical trials.

ADIL Adial Pharmaceuticals, Inc.: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 10/29/2026

adialpharma.com - analytical breakdowns and key metrics (ADIL)

- current price and projected stock value:

Stock Price Adial Pharmaceuticals, Inc.|ADIL - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value Adial Pharmaceuticals, Inc.|ADIL - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Adial Pharmaceuticals|ADIL - Company Net Assets|Market Capitalization to Book Value Ratio adialpharma.com|ADIL - Company Total Assets

- debt and solvency information:

Total Debt to Capital Adial Pharmaceuticals|ADIL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Adial Pharmaceuticals, Inc.|ADIL - Company Total Debt Obligations|Debts to Book Capitalization Adial Pharmaceuticals, Inc.|ADIL - Company Long-Term Debts|Company Short-Term Debt Adial Pharmaceuticals|Quick Liquidity Indicator adialpharma.com

- business earnings and investment ratios data:

ADIL - Final Profit|Expected Profit Adial Pharmaceuticals|ADIL - Market Cap to Net Income|Forward P/E Multiple Adial Pharmaceuticals, Inc.|ADIL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Adial Pharmaceuticals, Inc.|ADIL - Operating profit EBITDA|Earnings per share for the last twelve months Adial Pharmaceuticals|ADIL - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months adialpharma.com|ADIL - Net earnings per share growth this year|Earnings growth forecast for next year Adial Pharmaceuticals

Comprehensive company analysis:Adial ADIL

The EV/EBITDA ratio compares the total enterprise value of a business, including net debt, with its operating profit before depreciation and taxes. By analyzing the EV/EBITDA trajectory of a company, an investor identifies phases of asset overheating or undervaluation, minimizing the risks of emotional trading. For Adial Pharmaceuticals (ADIL), this metric is critical, as the dependence on AD04 patents renders future margins speculative.

Competitors of Adial Pharmaceuticals

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Collegium Corp COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGC (canopygrowth.com)|High Tide (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Aurora Cannabis Inc.|ACHV (Achieve Life Sciences, Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple skyebioscience.com|EV/EBITDA Multiple ANEB|intercure.co - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple NTRB (Nutriband)|Total Company Value to Operating Income Before Depreciation Ratio Nasus Pharma Ltd. (NSRX)|IGC Pharma Inc - EV/EBITDA Multiple|MIRA - EV/EBITDA Multiple|Flora Growth Corp. (FLGC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMCC (IM Cannabis) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio ARTL|ENSC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Titan Pharmaceuticals (TTNP)|GNLN: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple INM (InMed Pharmaceuticals)|Business Value to Operating Income Before Depreciation AKAN|Enveric Biosciences, Inc. - EV/EBITDA Multiple|BGXX - EV/EBITDA Multiple|Hempacco (HPCO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization